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Summary
This trial was conducted to determine the dose-limiting toxicities (DLTs)
and maximum tolerated dose (MTD) of the first in class NEDD8-activating
enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat
pharmacokinetics and pharmacodynamics in patients with acute myeloid
leukaemia (AML) and myelodysplastic syndromes (MDS). Pevonedistat was
administered via a 60-min intravenous infusion on days 1, 3 and 5 (sche-
dule A, n = 27), or days 1, 4, 8 and 11 (schedule B, n = 26) every 21-days.
Dose escalation proceeded using a standard ‘3 + 3’ design. Responses were
assessed according to published guidelines. The MTD for schedules A and
B were 59 and 83 mg/m2, respectively. On schedule A, hepatotoxicity was
dose limiting. Multi-organ failure (MOF) was dose limiting on schedule B.
The overall complete (CR) and partial (PR) response rate in patients trea-
ted at or below the MTD was 17% (4/23, 2 CRs, 2 PRs) for schedule A
and 10% (2/19, 2 PRs) for schedule B. Pevonedistat plasma concentrations
peaked after infusion followed by elimination in a biphasic pattern.
Pharmacodynamic studies of biological correlates of NAE inhibition dem-
onstrated target-specific activity of pevonedistat. In conclusion, administra-
tion of the first-in-class agent, pevonedistat, was feasible in patients with
MDS and AML and modest clinical activity was observed.
Keywords: MLN4924, acute myeloid leukaemia, NEDD8, NEDD8-activat-
ing enzyme, pevonedistat.
Acute myeloid leukaemia (AML) is predominantly a disease
of older patients and fatal for the majority (Burnett et al,
2009). Standard chemotherapy has remained essentially
unchanged over the last four decades with recent improve-
ments in survival largely attributable to better supportive
care and safer stem cell transplantation (SCT) techniques
(Burnett et al, 2007, 2009, 2010). Outcomes are particularly
poor for older patients considered unfit for conventional
chemotherapy (Burnett et al, 2007). Adverse biological fea-
tures are more common in these patients, making the disease
even more challenging to treat. Consequently, this contrib-
utes to rising AML mortality as the aging population contin-
ues to increase (Burnett et al, 2007, 2009, 2010). New
therapies are urgently needed.
The ubiquitin-proteasome system (UPS) is responsible for
regulated protein turnover in eukaryotic cells, and plays a
key role in a wide variety of cellular processes (Ciechanover,
2005; Hershko, 2005) Protein substrates degraded by the
UPS have roles in cell division, signal transduction, growth
and differentiation, and apoptosis (Adams, 2004; Herrmann
et al, 2007). Defects within the UPS have been shown to
underlie the pathogenesis of many diseases, including cancer
(Ciechanover, 2005; Hershko, 2005). Consequently, the UPS
is increasingly being investigated as a potential target for
anti-cancer agents (Adams, 2004; Herrmann et al, 2007). The
clinical activity of the proteasome inhibitor, bortezomib, in
multiple myeloma, mantle cell lymphoma and other tumour
types has demonstrated the validity of targeting this pathway
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(Reece et al, 2011; Kondagunta et al, 2004; Richardson et al,
2005; Fanucchi et al, 2006; Fisher et al, 2006; Treon et al,
2007; San Miguel et al, 2008; Goy et al, 2009). Within the
UPS, proteins are targeted for degradation by E3 ubiquitin
ligases through the addition of ubiquitin chains (polyubiqui-
tination) (Hershko, 2005). The Cullin-RING E3 ubiquitin
ligases (CRLs) are the largest family of E3 ligases. CRL activ-
ity requires conjugation of the ubiquitin-like protein NEDD8
(neural precursor cell-expressed, developmentally down-regu-
lated 8) to the cullin protein scaffold (‘neddylation’), which
is regulated by NEDD8-activating enzyme (NAE) (Gong &
Yeh, 1999; Read et al, 2000; Chiba & Tanaka, 2004; Petroski
& Deshaies, 2005). NAE activation of NEDD8 is therefore
essential for CRL activity and subsequent proteasomal
destruction of CRL substrates (Read et al, 2000; Chiba & Ta-
naka, 2004), which preclinical studies have shown to com-
prise approximately 20% of UPS-degraded proteins (Soucy
et al, 2009a).
Pevonedistat is a small molecule inhibitor of NAE (Soucy
et al, 2009a, 2010; Brownell et al, 2010; Lin et al, 2010; Mil-
hollen et al, 2010, 2011, 2012; Wang et al, 2011). In the pres-
ence of enzymatically active NAE, pevonedistat covalently
binds with NEDD8, forming a pevonedistat-NEDD8 adduct.
This adduct remains tightly bound to NAE. Consequently,
NAE is unable to process NEDD8 for CRL conjugation,
which leads to impaired CRL function and accumulation of
CRL dependent substrates (Brownell et al, 2010). Many of
these substrates have relevance in human cancers (Gstaiger
et al, 2001; Bloom & Pagano, 2003; Karin, 2006; Chen et al,
2010; Crusio et al, 2010), thus providing the rationale for
investigating pevonedistat as an anti-cancer agent. Preclinical
studies indicate that pevonedistat is cytotoxic to a range of
solid and haematopoietic tumour cell lines (Soucy et al,
2009a; Milhollen et al, 2010; Swords et al, 2010). Anti-
tumour activity has been demonstrated in several mouse
xenograft models including of AML (Soucy et al, 2009a,b;
Milhollen et al, 2010; Swords et al, 2010; Traore et al, 2010).
A variety of CRL substrates of relevance in AML have
potential anti-proliferative effects, with roles in cell cycle pro-
gression (p27), signal transduction, DNA damage (CDT1),
and the stress response (Nrf-2 [NFE2L2]) (Podust et al,
2000; Read et al, 2000; Petroski & Deshaies, 2005; Soucy
et al, 2009a; Brownell et al, 2010; Chen & Li, 2010; Milhollen
et al, 2010). Swords et al (2010) demonstrated that pevon-
edistat induced cell death at low nano-molar concentrations
in cell lines and primary patient material, independent of
FLT3 (Fms-like tyrosine kinase) expression and stromal med-
iated survival signals. Stabilization of key NAE targets con-
firmed pathway inhibition and disruption of cellular redox
was shown to be a key event in pevonedistat-mediated apop-
tosis. Treatment of mice bearing AML xenografts led to pro-
longed disease regression and inhibition of NEDDylated
cullins. Consequently, this first-in-human phase 1 study in
patients with AML or myelodysplastic syndromes (MDS) was
undertaken to investigate the safety, activity, pharmacokinet-
ics, and pharmacodynamics of two schedules of pevonedistat
(NCT00677170).
Materials and methods
Patients
Patients with relapsed and/or refractory AML or MDS for
which standard, curative or life-prolonging treatment did not
exist or was no longer effective were eligible. Patients
≥60 years old with untreated AML considered unfit for stan-
dard induction were also eligible. Other inclusion criteria
included: age of at least 18 years; Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of 0–2; adequate
renal function (calculated creatinine clearance >50 ml/min);
adequate hepatic function (total bilirubin ≤ normal, transam-
inases and alkaline phosphatase ≤25 9 upper limit of nor-
mal [ULN] and adequate cardiac function (B-type natriuretic
peptide ≤15 9 ULN, left ventricular ejection fraction ≥45%
and pulmonary artery systolic pressure ≤15 9 ULN). Strict
cardiac inclusion criteria were employed because pulmonary
hypertension was observed at higher doses of pevonedistat in
animal models. Exclusion criteria included: treatment with
an investigational anti-leukaemic agent within 14 days prior
to entering study; documented history of allergic reactions to
compounds of similar chemical or biological composition to
pevonedistat; pregnancy or breastfeeding; uncontrolled inter-
current illness and known infection with human immunode-
ficiency virus and/or viral hepatitis B or C. Institutional
review boards at all participating institutions approved the
study, which was conducted in accordance with Good Clini-
cal Practice guidelines.
Study design
This open-label, phase 1, dose-escalation study
(NCT00911066) was conducted at six sites across the United
States. The primary objectives were to determine the dose-
limiting toxicities (DLT) and maximum tolerated doses
(MTD) of pevonedistat. Secondary objectives included
descriptions of pevonedistat pharmacokinetics (PK) in
plasma, pharmacodynamic (PD) effects of pevonedistat in
leukaemic blasts and whole blood and a preliminary assess-
ment of anti-tumour activity.
Pevonedistat was administered via a 60-min intravenous
(IV) infusion on days 1, 3 and 5 (schedule A), or days 1, 4,
8 and 11 (schedule B). Cycles were repeated every 21 days.
Dose escalation started at 25 and 147 mg/m2 for schedules A
and B, respectively, and MTD determination was based on a
standard ‘3 + 3’ design. Dose escalation terminated when 2
(or more) of 6 patients experienced a DLT at the same dose
level. The MTD was defined as the highest dose that gener-
ated a DLT rate of 0/6 or 1/6 patients during Cycle 1. DLTs
were defined in Cycle 1 only as any grade ≥3 toxicity related
to pevonedistat (exceptions were: arthralgia/myalgia, fatigue
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<1 week, hypophosphataemia and prolonged prothrombin
time/activate partial thromboplastin time without clinical
bleeding).
Safety and efficacy assessments
Patient demographics and medical history were recorded at
baseline. Adverse event assessments, physical examination,
vital signs and ECOG performance status were documented
at baseline and every week for the duration of the trial.
Safety was assessed from informed consent to 30 days after
final dose of pevonedistat. Adverse events (AE) were graded
according to the National Cancer Institute’s Common Ter-
minology Criteria for AEs, version 3.0 (NCI CTEP, 2011).
Patients with AML were assessed for efficacy according to
published International Working Group criteria (Cheson
et al, 2003). Responses in MDS were described descriptively.
Pharmacokinetic and pharmacodynamic analyses
Blood samples for PK and PD analyses were collected simul-
taneously during Cycle 1 at multiple time points, pre- and
post-infusion for each schedule. Non-compartmental analyses
(using WinNonlin software, Version 6.2, Pharsight Corpora-
tion, Cary, NC, USA) were used to estimate the observed
maximum concentration (Cmax; theoretically end-of-infusion
concentration), the time at which Cmax occurred (Tmax), the
area under the plasma concentration-time curve from time 0
to 24 h post-dose (AUC24 h), the area under the plasma con-
centration-time curve from time 0 to the end of the dosing
interval (AUC0-tau) and, data permitting, the terminal dispo-
sition phase half-life (t1/2).
For PD assessments, the expression levels of 8 mRNA
transcripts (ATF3, GCLM, GSR, AGPAT9, NQO1, SLC7A11,
SRXN1, and TXNRD1) were measured in the peripheral
blood. These transcripts were previously identified as induced
by pevonedistat-mediated NAE inhibition (Walker et al,
2011). Percentage change in RT-PCR expression level over
baseline was calculated for each gene. In addition, pre- and
post-dose bone marrow samples were collected at screening
and 3 to 6 h after the second (Day 4 of schedule B) or third
(Day 5 of schedule A) dose of pevonedistat. Immunohisto-
chemistry (IHC) was used to assess tissue biomarkers of
NAE inhibition in leukaemic blasts [pevonedistat-NEDD8
adduct formation and change in CDT1 levels, as previously
described (Shinde et al, 2014)].
Results
Patient characteristics
Fifty-three patients were treated with either schedule A
(n = 27) or schedule B (n = 26). Of these, the most common
diagnosis was AML (n = 50, 94%). Three patients (6%) were
enrolled with MDS. Patients enrolled were heavily pre-treated
and included 17 patients (32%) who had prior SCT. Only
three patients (6%) were treatment-naive. Pertinent demo-
graphics are presented in Table I.
Dose escalation and MTD determination
Patients on schedule A (Days 1,3,5) began escalating doses of
pevonedistat at 25 (n = 3), 33 (n = 4), 44 (n = 3), 59
(n = 3) and 78 mg/m2 (n = 4) mg/m2. At the 78 mg/m2
dose level, one patient experienced grade 3 elevation in trans-
aminases after one dose of pevonedistat, meeting criteria for
DLT. This patient was successfully re-challenged with 59 mg/
m2 before coming off study during Cycle 4 for disease pro-
gression. Another patient treated with 78 mg/m2, received 4
doses of pevonedistat and, on Cycle 2 day 3, presented with
sepsis syndrome, elevated transaminases and multi-organ
Table I. Demographics and baseline disease characteristics.
Characteristic Schedule A n = 27 Schedule B n = 26
Median age,
years (range)
591 (29–84) 627 (19–83)
Male, n (%) 17 (63) 20 (77)
Race, n (%)
White 23 (85) 25 (96)
Asian 3 (11) 1 (4)
Other 1 (4) 0
ECOG performance status, n (%)
0 6 (22) 5 (19)
1 16 (59) 16 (62)
2 5 (19) 5 (19)
Median time from
initial diagnosis (months)
114 127
Primary diagnosis, n (%)
AML 26 (96) 24 (92)
FAB
M0 2 (7) 2 (8)
M1 4 (15) 2 (8)
M2 6 (22) 1 (4)
M3 0 0
M4 1 (4) 2 (8)
M5 2 (7) 4 (15)
M6 0 0
M7 1 (4) 0
NOS* 8 (30) 13 (50)
Unclassifiable 1 (4) 0
Missing 1 (4) 0
Cytogenetics*
Favourable 1 (4) 0
Intermediate 12 (44) 10 (38)
Adverse 9 (33) 10 (38)
Undetermined 5 (19) 6 (23)
MDS* 1 (4) 2 (8)
*Cytogenetic data were reported as per Cancer and Leukemia Group
B criteria (Byrd et al, 2002).
ECOG, Eastern Cooperative Oncology Group; AML, acute myeloid
leukaemia; FAB, French-American-British classification; NOS, not
otherwise specified; MDS, myelodysplastic syndromes.
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failure (MOF), which was fatal. This AE, considered related
to pevonedistat, happened outside the DLT period. Although
the protocol allowed for further dose escalation, severe liver
toxicity and MOF had by then been reported in a parallel
study of pevonedistat in patients with solid tumours, using a
continuous dosing schedule (Kauh et al, 2011). Considering
this, higher dose levels were not tested on schedule A and
the MTD was determined to be 59 mg/m2. An additional 10
patients were enrolled at this dose level and no further DLTs
were reported.
Following completion of schedule A, dose escalation for
schedule B patients (Days 1,4,8,11) began at 147 mg/m2. The
higher starting dose and schedule change was based on then
emerging laboratory and clinical experience with pevonedi-
stat. In murine xenograft models, we observed a direct expo-
sure-response relationship, which was schedule-independent.
Accordingly, we hypothesized that higher cumulative doses
of pevonedistat per cycle, would be more clinically active. In
a phase I trial of pevonedistat for patients with lymphoma
and myeloma (n = 16), pevonedistat was given on Days
1,4,8,11 and dose escalation began at 110 mg/m2 (Shah et al,
2009). Only one DLT was reported (grade 3 thrombocytope-
nia at 110 mg/m2), and pevonedistat plasma exposure did
not accumulate between doses. The MTD was 196 mg/m2 on
this study and objective responses were reported at this dose
level. Grade 3/4 hepatoxicity was not reported. Given the
higher cumulative start dose being tested on schedule B and
the schedule A MTD, enrollment into the first cohort was
staggered. Two patients experienced DLT on this cohort
(MOF leading to cardiac failure and death). Both events
occurred after a single dose of pevonedistat. Dose de-escala-
tion to 110 mg/m2 proceeded and an additional DLT was
reported (orthostatic hypotension; the patient subsequently
died of MOF). A fatal fungal pneumonia was also reported
in this cohort but did not meet criteria for DLT (unrelated
to pevonedistat). Given the severity of both events, dose
reduction continued to 83 mg/m2. No further DLT were
reported in 19 patents enrolled at this dose level and 83 mg/
m2 was declared the MTD for schedule B.
Safety
Patients on schedules A and B were treated for medians of 2
(range 1–19) and 2 (range 1–13) cycles, respectively. All
patients were evaluable for toxicity. The majority of AE were
mild or moderate (grade 1 or 2); the most common are shown
in Table II. Febrile neutropenia, thrombocytopenia and ele-
vated aspartate transaminase (AST) levels were the most fre-
quent grade ≥3 AE reported (occurring in 2 or more patients).
Patients with at least 1 treatment-related grade ≥3 AE included
8 (30%) on schedule A and 12 (46%) on schedule B (Table II).
Drug-related severe AE (SAE) leading to discontinuation of
therapy included one patient (4%) on schedule A (sepsis) and
two patients (8%) on schedule B (1 due to MOF, 1 due to
heart failure). Deaths related to pevonedistat occurred in three
patients with AML, 1 from sepsis on schedule A (78 mg/m2
dose cohort) and 2 from MOF on schedule B (1 each in the
110 mg/m2 and 147 mg/m2 dose cohorts).
Pharmacokinetics
The PK-evaluable population included 19 (70%) and 17
(65%) patients on schedules A and B, respectively. Mean
pevonedistat plasma concentration-time profiles obtained
Table II. Treatment-emergent adverse event (AE) experienced by
≥10% of patients on any schedule.
AE, n (%)
Schedule A
n = 27
Schedule B
n = 26
Total
n = 53
Any AE 27 (100) 26 (100) 53 (100)
Pyrexia 12 (44) 16 (62) 28 (53)
Diarrhoea 14 (52) 9 (35) 23 (43)
Febrile neutropenia 11 (41) 8 (31) 19 (36)
Chills 8 (30) 11 (42) 19 (36)
Decreased appetite 11 (41) 7 (27) 18 (34)
Fatigue 9 (33) 9 (35) 18 (34)
Peripheral oedema 11 (41) 6 (23) 17 (32)
Nausea 10 (37) 7 (27) 17 (32)
Dyspnoea 6 (22) 10 (38) 16 (30)
Dizziness 11 (41) 4 (15) 15 (28)
Myalgia 8 (30) 7 (27) 15 (28)
Vomiting 8 (30) 5 (19) 13 (25)
Cough 7 (26) 6 (23) 13 (25)
Aspartate transaminase
increased
9 (33) 3 (12) 12 (23)
Alanine transaminase
increased
8 (30) 4 (15) 12 (23)
Headache 5 (19) 7 (27) 12 (23)
Epistaxis 6 (22) 6 (23) 12 (23)
Rales 9 (33) 2 (8) 11 (21)
Hypokalaemia 4 (15) 6 (23) 10 (19)
Thrombocytopenia 5 (19) 5 (19) 10 (19)
Constipation 6 (22) 4 (15) 10 (19)
Abdominal pain 7 (26) 3 (12) 10 (19)
Confusion 6 (22) 4 (15) 10 (19)
Pneumonia 5 (19) 4 (15) 9 (17)
Pain 4 (15) 5 (19) 9 (17)
Hypocalcaemia 4 (15) 4 (15) 8 (15)
Hyperbilirubinaemia 3 (11) 5 (19) 8 (15)
Stomatitis 5 (19) 3 (12) 8 (15)
Hypoalbuminaemia 4 (15) 4 (15) 8 (15)
Hypoxia 6 (22) 2 (8) 8 (15)
Any Grade ≥3 AE, n (%)*
Thrombocytopenia 2 (7) 2 (8) 4 (8)
Febrile neutropenia 0 2 (8) 2 (4)
Increased aspartate
transaminase
2 (7) 0 2 (4)
Hypoxia 1 (4) 1 (4) 2 (4)
Hypotension 1 (4) 1 (4) 2 (4)
Multi-organ failure 0 2 (8) 2 (4)
Fatigue 2 (7) 0 2 (4)
*Grade 3 treatment related AEs occurring in >1 patient overall.
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on Day 1 of Cycle 1 are shown in Fig 1. Following IV
infusion on Day 1, individual concentration-time profiles
declined in a bi-exponential manner, reflecting a rapid dis-
tribution of pevonedistat from plasma to peripheral tissues
followed by a slower phase, reflecting eventual elimination
from the body. Plasma concentrations were generally quan-
tifiable up to 24 h post-infusion at doses of 25 and 33 mg/
m2 and up to 48 h post-infusion at doses of 44 mg/m2 or
above. Relevant PK parameters of pevonedistat for both
schedules are summarized in Table III. Observed increases
in mean Cmax and AUC24 h were approximately dose pro-
portional between the 25 and 83 mg/m2 doses after single
dosing. Inter-individual variability in pevonedistat systemic
exposure was modest across the various dosing cohorts (%
CV ≤31%).
Pharmacodynamics
Across all dose levels tested, induction of 8 target genes
known to be induced by pevonedistat-mediated NAE inhi-
bition (Walker et al, 2011) was confirmed. Fig 2A shows
expression levels of one of these genes (NQO1) across 25
patients treated on schedule A. Increases in gene expres-
sion occurred in most patients within 4 to 8 h upon IV
infusion of pevonedistat, and returned close to baseline
within 24 h, consistent with the observed elimination of
pevonedistat from the systemic circulation. Immunohisto-
chemical assays for the presence of pevonedistat-NEDD8
adduct confirmed NAE inhibition in leukaemic blasts in
32 of 35 post-dose samples analysed. In three cases, adduct
was detected in the sample labelled ‘pre-dose’ but not in
the post-dose sample,indicating a sample switch, these
pairs were therefore excluded from the final analysis
(Fig 2B). Additionally, the CRL substrate CDT1, was seen
to accumulate in tumour tissue following dosing, providing
a downstream indication of NEDD8 pathway inhibition by
pevonedistat (Fig 2B and C).
Efficacy
For patients that received doses at or below the MTD
(n = 23), two complete responses (CRs, 8%) and two partial
responses (PRs, 8%) were documented for a CR/PR rate of
17% on schedule A. On schedule B, there were 2 PRs (10%)
documented in those treated at the MTD (n = 19). One
patient each in the 44 mg/m2 cohort of Schedule A, the
83 mg/m2 cohort of Schedule B and the 25 mg/m2 cohort of
Schedule A, maintained a response for over 12, 10 and
5 months, respectively. All responses documented were in
patients with AML. Prolonged stable disease (defined as
treatment with ≥5 cycles without evidence of progression or
response) was reported in 6 (11%) patients, 4 (15%) on
schedule A and 2 (8%) on schedule B. Of the three patients
with MDS treated, one patient achieved stable disease beyond
5 cycles of therapy (78 mg/m2 cohort on schedule A).
Responses are summarized in Table IV.
Discussion
In this first-in-human study, two intermittent dosing sched-
ules, selected based on ongoing trials of pevonedistat in other
tumour types, were examined. In a phase I study in patients
with solid tumours, continuous dosing caused severe liver
toxicity and two patients died (due to MOF and disease
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progression). Consequently, further testing was held and
intermittent schedules (on days 1, 3 and 5) were explored,
permitting recovery of hepatic transaminases between doses.
This study formed the basis for the design of schedule A.
Doses beyond 78 mg/m2 could have been tested on this sche-
dule, since only one DLT was reported at this dose level.
However, as development of pevonedistat continued, sche-
dule B was opened to test the hypothesis that higher cumula-
tive doses per cycle would be more biologically active. In
another phase I study for patients with lymphoma and mye-
loma (Harvey et al, 2012), schedule B had already been
examined and MTD was declared at 196 mg/m2. In the cur-
rent trial, dose de-escalation from 147 mg/m2 to 83 mg/m2
(MTD) occurred on this schedule due to MOF in 3 patients
with AML. These events led to a series of pre-clinical studies
to explore potential mechanism-based toxicity. Rodents trea-
ted with combined pevonedistat and TNF-a (but not with
single agents alone) exhibited a sepsis-like response, associ-
ated with increased circulating cytokines, organ damage
(liver, kidney and gastro-intestinal tract) and elevated mark-
ers of tissue injury (alanine transaminase [ALT], AST, biliru-
bin and creatinine) (Wolenski et al, 2013). In cell-based
assays, pevonedistat was shown to potentiate TNF-a signal-
ling through activation of JNK kinase (Wolenski et al, 2013).
Collectively, these data suggest that at higher dose levels of
pevonedistat, an aberrant cytokine response may have con-
tributed to the MOF observed on this trial.
Although some variability was apparent between cohorts
and patients, pevonedistat plasma exposure increased propor-
tionately with dose across the 25–83 mg/m2 dose range.
Where it could be assessed, plasma pevonedistat half-life was
estimated to be around 12 h (Table III), which is consistent
with PK findings from other pevonedistat clinical studies
(Shah et al, 2009; Bhatia et al, 2011; Kauh et al, 2011;
Harvey et al, 2010). To explore pevonedistat pharmacody-
namics, we designed a novel immunohistochemical approach
to measure pevonedistat-NEDD8 adduct formation. Given
that the adduct will only form in the presence of enzymati-
cally active NAE, we demonstrated NAE inhibition directly
in leukaemic blasts. Furthermore, when we tested for accu-
mulation of the CRL substrate CDT1 as a consequent effect
of NAE inhibition (as previously demonstrated in xenograft
studies (Soucy et al, 2009a), we confirmed a ≥15-fold
increase in CDT1 expression in 16 of 29 (55%) evaluable
patients, confirming pathway inhibition by pevonedistat at
all doses tested. However, the amplitude of CDT1 expression
did not predict for response in this study. We looked at
expression levels of 8 NAE regulated target genes in whole
blood. Induction of all 8 genes was observed, further con-
firming NAE inhibition by pevonedistat.
Pevonedistat showed clinical activity in relapsed refrac-
tory AML patients. Noteworthy responses included a 71-
year-old male with primary induction failure who received
44 mg/m2 and achieved a PR before coming off study for
disease progression after 19 cycles of therapy. Additionally,
two patients with recent relapses after allogeneic SCT for
AML responded on study. The first patient was enrolled at
the lowest dose level (25 mg/m2) and achieved a complete
cytogenetic remission, which was maintained for seven
cycles. The second patient achieved a PR and was treated at
25 mg/m2. The possibility that pevonedistat might augment
a graft-versus-leukaemia effect is intriguing and currently
under investigation. Despite attempts to increase pevonedi-
stat exposure in this and other studies (Kauh et al, 2009,
2011; Shah et al, 2009; Bhatia et al, 2011), most of the
responses we observed on this study were observed at lower
doses. It is possible that after NAE is fully inhibited, that
higher doses of pevonedistat may not confer additional clin-
ical benefit but may cause increased toxicity (at least for
patients with AML).
Table III. Pevonedistat pharmacokinetic parameters following a 1-h intravenous infusion in patients treated on schedules A and B.
Parameter (unit)
Pevonedistat Dose (mg/m2)
Schedule A Schedule B
25 33 44 59 (MTD) 78 83 (MTD)
n = 2 n = 4 n = 3 n = 6 n = 4 n = 17
Cmax (ng/ml) 222 374 (22) 431 (18) 648 (28) 1173 (31) 1212 (25)
Tmax (h)* 107 (11,11) 108 (11,12) 103 (10,11) 108 (09,16) 104 (10,12) 105 (09,13)
AUC24 h (ng.h/ml) 1034 1419 (12) 1916 (17) 2506 (28) 3857 (17) 3869 (22)
AUC0-t (ng.h/ml) 1829† 2913 (19)‡ 3790 (15)§
With the exception of one patient on Schedule B (83 mg/m2), the elimination half-life of pevonedistat could not be accurately estimated due to
insufficient sampling in the terminal disposition phase; in this patient, t1/2 was estimated to be 12 h in plasma. All other parameters were
recorded as shown.
Parameters are presented as geometric means (% coefficient of variance) unless specified otherwise. *Median (range); Schedule A: pevonedistat
dosing on Days 1, 3 and 5 followed by a rest period of 16 days; Schedule B: pevonedistat dosing on Days 1, 4, 8 and 11 followed by a rest period
of 10 days.
†n = 2; ‡n = 5; §n = 3.
MTD, maximum tolerated dose.
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(A)
(B)
(C)
Fig 2. (A) Percent change from baseline in NQO1 expression in blood following pevonedistat dosing at 25–78 mg/m2 on schedule A. Colored
lines represent individual patients across the 5 dose levels explored in Schedule A (3 at 25 mg/m2, 4 at 33 mg/m2, 3 at 44 mg/m2, 11 at 59 mg/
m2 and 4 at 78 mg/m2). NQO1 mRNA levels are presented as change from baseline (pre-dose) during the 24 h period following pevonedistat
dosing on Day 1 and four hours after dosing on Day 5. The y-axis of the 59 mg/m2 plot was capped at change from baseline of 1000% for clarity,
the data at 8 h and 99 h off scale were >500 000 and 2000% change respectively. (B) Representative immunohistochemistry images of bone mar-
row clot preparations stained for pevonedistat-NEDD8-adduct and CDT1. Bone marrow aspirate (from a patient treated on Schedule A at
44 mg/m2) at screening (A1 and B1) and 3–6 h post-third dose of pevonedistat (A2 and B2), stained via immunohistochemistry for pevonedi-
stat-NEDD8-adduct (brown is positive) and CDT1 (brown identifies CD34/CD117 + cells and blue is CDT1). All images contain a 20X image, a
zoomed out thumbnail view of the block (top right) and a zoomed-in image (bottom right). Black arrows indicate representative cells that were
detected as CD117/34 + and CDT1+. The post-dose increase in percentage of CDT1 positivity reported for this patient was +13-fold. (C) Fold
change in the percentage of CDT1 positive CD117 + /CD34 + cells by immunohistochemistry in bone marrow before and after pevonedistat dos-
ing. Data are represented as individual patient data (open circles), with median upper and lower quartile (box) and 95% confidence limits (whis-
kers) plotted per dose group. Dose groups 25–78 mg/m2 were from Schedule A (post-dose sample Cycle 1, Day 5) and dose groups 83–110 mg/
m2 were from Schedule B. Red filled circles represent responding patients (complete or partial response).
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This first-in-human study confirms that treatment with
the NAE inhibitor pevonedistat is a feasible new investiga-
tional approach for patients with AML. Based on relative
ease of administration (3 doses in 1 week followed by
2 weeks off), convenience in terms of future combination
therapies and the data reported in this trial, schedule A has
been selected for further clinical development. We are con-
fident that this schedule reflects the most clinically and
biologically active approach, which will be confirmed in
larger studies. The incidence of pevonedistat-associated
myelosuppression was low on this study, making it a
potentially good candidate for combinations with other
established anti-leukaemic agents. Combined therapy with
hypomethylating agents (Smith et al, 2011) and cytarabine
(Nawrocki et al, 2010) has already been explored in pre-
clinical models, and a phase Ib investigation of pevonedi-
stat combined with azacitidine is ongoing in patients with
AML (NCT01814826). An interim analysis of this study
was recently presented (Swords et al, 2014). Previously
untreated AML patients ≥60 years old, considered unfit or
unlikely to benefit from standard induction chemotherapy,
were treated with escalating doses of pevonedistat given on
days 1, 3 and 5, combined with fixed doses of azacitidine
(75 mg/m2 IV/SC on days 1–5 and days 8–9). Cycles were
repeated every 28 days. At data cut-off (April 2014), 22
patients had received pevonedistat at 20 mg/m2 (n = 19)
and 30 mg/m2 (n = 3). One patient each had grade 3 AST
elevation and grade 2 elevated bilirubin at pevonedistat
30 mg/m2 that was dose-limiting. One DLT (grade 4 AST/
ALT elevation) occurred in 19 patients treated at the MTD
(pevonedistat 20 mg/m2 plus IV/SC azacitidine 75 mg/m2).
The most common AEs reported were myelosuppression
and constipation. The PK profile of pevonedistat on this
study did not change significantly with the addition of aza-
citidine. In the 15 patients evaluable for response, the CR/
PR rate was 53% (4 CRs, 2 PRs). In this study, the addi-
tion of pevonedistat to azacitidine was feasible, and justifies
the conduct of other rational pevonedistat combination
trials in AML.
In the future, treatment emergent mutations may arise
as mechanisms of resistance to pevonedistat. In cell lines
and xenograft models, heterozygous mutations in the ATP
binding pocket and substrate binding cleft of NAE, were
identified as primary mechanisms of resistance to pevonedi-
stat (Milhollen et al, 2012). An amino acid substitution
(A171T) in the adenylate binding site was the most fre-
quent mutation detected. A pan-E1 inhibitor with tighter
binding properties was able to potently inhibit mutant
enzymes in cells. These data provide a rationale for patient
selection and the development of next-generation NAE
inhibitors designed to overcome treatment-emergent muta-
tions in the clinic. Larger planned studies of pevonedistat
will provide more patients to profile for mechanisms of
pevonedistat resistance. In conclusion, the results of the
currently reported study indicate that NAE may be a novel
therapeutic target and justify further study of pevonedistat,
particularly in patients with AML.
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Table IV. Anti-leukaemic activity of pevonedistat for both schedules
Schedule Dose (mg/m2) Disease response Patients
A* 25 CR 1
A† 33 CR 1
A‡ 44 PR 1
A§ 59 PR 1
B¶,** 83 PR 2
*29-year-old female with acute myeloid leukaemia (AML) and
adverse cytogenetics relapsing post-stem cell transplantation (SCT).
Achieved a complete cytogenetic remission that was maintained for 7
cycles of therapy until disease progression.
†82-year-old male with AML and prior azacitidine failure, achieved
stable disease for 8 cycles of therapy and then achieved a complete
remission (CR) by Cycle 10, which lasted 27 months.
‡71-year-old with AML and primary induction failure achieved a
partial response (PR) after 2 cycles of therapy and remained on
study for 19 cycles.
§51-year-old with AML relapsing post-SCT achieved a PR after one
cycle of therapy.
¶78-year-old male with refractory AML (conventional chemotherapy,
azacitidine) achieved a PR after Cycle 1 and remained on study for
13 cycles before being withdrawn due to disease progression.
**73-year-old female with azacitidine-refractory AML achieved a PR
following Cycle 1 of therapy.
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